BioXcel Therapeutics Inc (NASDAQ: BTAI) kicked off on Friday, up 3.94% from the previous trading day, before settling in for the closing price of $2.79. Over the past 52 weeks, BTAI has traded in a range of $1.91-$29.56.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 53.60% over the last five years. While this was happening, its average annual earnings per share was recorded 61.00%. With a float of $24.56 million, this company’s outstanding shares have now reached $29.93 million.
The firm has a total of 74 workers. Let’s measure their productivity.
BioXcel Therapeutics Inc (BTAI) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of BioXcel Therapeutics Inc is 26.96%, while institutional ownership is 28.05%. The most recent insider transaction that took place on Apr 04 ’24, was worth 13,823. In this transaction CEO and President of this company sold 5,268 shares at a rate of $2.62, taking the stock ownership to the 43,564 shares. Before that another transaction happened on Apr 04 ’24, when Company’s Chief Financial Officer sold 1,069 for $2.63, making the entire transaction worth $2,817. This insider now owns 4,765 shares in total.
BioXcel Therapeutics Inc (BTAI) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of 1.75 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 61.00% per share during the next fiscal year.
BioXcel Therapeutics Inc (NASDAQ: BTAI) Trading Performance Indicators
Take a look at BioXcel Therapeutics Inc’s (BTAI) current performance indicators. Last quarter, stock had a quick ratio of 2.57. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 70.67.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -6.16, a number that is poised to hit -0.74 in the next quarter and is forecasted to reach -2.00 in one year’s time.
Technical Analysis of BioXcel Therapeutics Inc (BTAI)
Analysing the last 5-days average volume posted by the [BioXcel Therapeutics Inc, BTAI], we can find that recorded value of 0.48 million was lower than the volume posted last year of 1.42 million. As of the previous 9 days, the stock’s Stochastic %D was 54.57%. Additionally, its Average True Range was 0.20.
During the past 100 days, BioXcel Therapeutics Inc’s (BTAI) raw stochastic average was set at 41.08%, which indicates a significant decrease from 63.75% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 45.75% in the past 14 days, which was lower than the 126.59% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.98, while its 200-day Moving Average is $4.28. Now, the first resistance to watch is $3.07. This is followed by the second major resistance level at $3.25. The third major resistance level sits at $3.40. If the price goes on to break the first support level at $2.75, it is likely to go to the next support level at $2.60. Should the price break the second support level, the third support level stands at $2.43.
BioXcel Therapeutics Inc (NASDAQ: BTAI) Key Stats
The company with the Market Capitalisation of 97.53 million has total of 30,577K Shares Outstanding. Its annual sales at the moment are 1,380 K in contrast with the sum of -179,050 K annual income. Company’s last quarter sales were recorded 380 K and last quarter income was -22,260 K.
